A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Procedure: Bone marrow aspirate
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT02663752
- Locations
- 🇧🇪
Novartis Investigative Site, Liege, Belgium
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1002
- Registration Number
- NCT02661217
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: Ligelizumab
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 226
- Registration Number
- NCT02649218
- Locations
- 🇬🇧
Novartis Investigative Site, Yeovil, Somerset, United Kingdom
Rainbow Extension Study
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT02640664
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
- Conditions
- Wet Age-related Macular Degeneration (Wet AMD)
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02634970
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02634983
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- Conditions
- cMET-dysregulated Advanced Solid Tumors
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02626234
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta, Georgia, United States
A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)
- Conditions
- Chronic Urticaria
- Interventions
- Other: Non Interventional Study
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 497
- Registration Number
- NCT02626221
- Locations
- 🇵🇪
Novartis Investigative Site, San Martin de Porres, Lima, Peru
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02625922
- Locations
- 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
- Conditions
- FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)Acute Myeloid Leukemia (AML) With
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02624570
- Locations
- 🇺🇸
City of Hope National Medical Center Department of Hematology & HCT, Duarte, California, United States
🇺🇸The Jordan Research and Education Center ABSMC Comprehensive Cancer Ctr, Berkeley, California, United States
🇺🇸St. Judes Medical Center, Fullerton, California, United States